Immunotherapy for gastric cancer: dilemmas and prospect

Abstract Gastric cancer remains the second most common cause of cancer-related death worldwide. Because of the poor prognosis of late-stage gastric cancer patients, it is imperative to develop new strategies to improve the survival rate of this disease. Currently, immunotherapy is considered as an i...

Full description

Saved in:
Bibliographic Details
Published inBriefings in functional genomics Vol. 18; no. 2; pp. 107 - 112
Main Authors Zhao, Qingfang, Cao, Liang, Guan, Lulu, Bie, Liangyu, Wang, Saiqi, Xie, Bojian, Chen, Xiaobing, Shen, Xiaokun, Cao, Feiling
Format Journal Article
LanguageEnglish
Published England Oxford University Press 22.03.2019
Subjects
biomarkers
breast neoplasms
death
genome
genomics
immune system
immunotherapy
lung neoplasms
prognosis
stomach neoplasms
survival rate
immunogenomics
immune checkpoint inhibitor
gastric cancer
biomarkers
Online AccessGet full text

Cover

Abstract Abstract Gastric cancer remains the second most common cause of cancer-related death worldwide. Because of the poor prognosis of late-stage gastric cancer patients, it is imperative to develop new strategies to improve the survival rate of this disease. Currently, immunotherapy is considered as an innovative approach for cancers such as lung cancer, gastric cancer and breast cancer. In fact, previous works have revealed promising results in this field. With further understanding of immunogenomics of gastric cancer, new immune checkpoint regulators could become more important. In addition, whole-genome sequencing and genome editing provide us with more information on the heterogeneity of gastric cancer, showing helpful tools to identify new predictive biomarkers and to achieve personalized treatment. Further research and better understanding of the functions of immune system will enhance immunotherapy treatment in the future.
AbstractList Gastric cancer remains the second most common cause of cancer-related death worldwide. Because of the poor prognosis of late-stage gastric cancer patients, it is imperative to develop new strategies to improve the survival rate of this disease. Currently, immunotherapy is considered as an innovative approach for cancers such as lung cancer, gastric cancer and breast cancer. In fact, previous works have revealed promising results in this field. With further understanding of immunogenomics of gastric cancer, new immune checkpoint regulators could become more important. In addition, whole-genome sequencing and genome editing provide us with more information on the heterogeneity of gastric cancer, showing helpful tools to identify new predictive biomarkers and to achieve personalized treatment. Further research and better understanding of the functions of immune system will enhance immunotherapy treatment in the future.
Abstract Gastric cancer remains the second most common cause of cancer-related death worldwide. Because of the poor prognosis of late-stage gastric cancer patients, it is imperative to develop new strategies to improve the survival rate of this disease. Currently, immunotherapy is considered as an innovative approach for cancers such as lung cancer, gastric cancer and breast cancer. In fact, previous works have revealed promising results in this field. With further understanding of immunogenomics of gastric cancer, new immune checkpoint regulators could become more important. In addition, whole-genome sequencing and genome editing provide us with more information on the heterogeneity of gastric cancer, showing helpful tools to identify new predictive biomarkers and to achieve personalized treatment. Further research and better understanding of the functions of immune system will enhance immunotherapy treatment in the future.
Gastric cancer remains the second most common cause of cancer-related death worldwide. Because of the poor prognosis of late-stage gastric cancer patients, it is imperative to develop new strategies to improve the survival rate of this disease. Currently, immunotherapy is considered as an innovative approach for cancers such as lung cancer, gastric cancer and breast cancer. In fact, previous works have revealed promising results in this field. With further understanding of immunogenomics of gastric cancer, new immune checkpoint regulators could become more important. In addition, whole-genome sequencing and genome editing provide us with more information on the heterogeneity of gastric cancer, showing helpful tools to identify new predictive biomarkers and to achieve personalized treatment. Further research and better understanding of the functions of immune system will enhance immunotherapy treatment in the future.Gastric cancer remains the second most common cause of cancer-related death worldwide. Because of the poor prognosis of late-stage gastric cancer patients, it is imperative to develop new strategies to improve the survival rate of this disease. Currently, immunotherapy is considered as an innovative approach for cancers such as lung cancer, gastric cancer and breast cancer. In fact, previous works have revealed promising results in this field. With further understanding of immunogenomics of gastric cancer, new immune checkpoint regulators could become more important. In addition, whole-genome sequencing and genome editing provide us with more information on the heterogeneity of gastric cancer, showing helpful tools to identify new predictive biomarkers and to achieve personalized treatment. Further research and better understanding of the functions of immune system will enhance immunotherapy treatment in the future.
Author Guan, Lulu
Zhao, Qingfang
Xie, Bojian
Wang, Saiqi
Chen, Xiaobing
Cao, Feiling
Shen, Xiaokun
Bie, Liangyu
Cao, Liang
Author_xml – sequence: 1
  givenname: Qingfang
  surname: Zhao
  fullname: Zhao, Qingfang
  organization: Zhengzhou University, Zhengzhou, China
– sequence: 2
  givenname: Liang
  surname: Cao
  fullname: Cao, Liang
  organization: The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, China
– sequence: 3
  givenname: Lulu
  surname: Guan
  fullname: Guan, Lulu
  organization: Zhengzhou University, Zhengzhou, China
– sequence: 4
  givenname: Liangyu
  surname: Bie
  fullname: Bie, Liangyu
  organization: Department of Internal Oncology, Henan Cancer Hospital, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China
– sequence: 5
  givenname: Saiqi
  surname: Wang
  fullname: Wang, Saiqi
  organization: Department of Internal Oncology, Henan Cancer Hospital, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China
– sequence: 6
  givenname: Bojian
  surname: Xie
  fullname: Xie, Bojian
  organization: Department of Surgical Oncology, Taizhou Hospital, Wenzhou Medical University, Taizhou, China
– sequence: 7
  givenname: Xiaobing
  surname: Chen
  fullname: Chen, Xiaobing
  email: 2290773710@qq.com
  organization: Department of Internal Oncology, Henan Cancer Hospital, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China
– sequence: 8
  givenname: Xiaokun
  surname: Shen
  fullname: Shen, Xiaokun
  email: shenven@hotmail.com
  organization: Department of Surgical Oncology, Taizhou Hospital, Wenzhou Medical University, Taizhou, China
– sequence: 9
  givenname: Feiling
  surname: Cao
  fullname: Cao, Feiling
  email: tzyyrjk@hotmail.com
  organization: Department of Surgical Oncology, Taizhou Hospital, Wenzhou Medical University, Taizhou, China
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30388190$$D View this record in MEDLINE/PubMed
BookMark eNqF0ElLAzEUB_Agiq21J-8yJxFkbJbJTOJNikuh4EXPIZOljsxmkjn025syLYiI5pIcfu_lvf8ZOG671gBwgeAtgpwsSrvpF6beQsSPwBTDDKU4p8Xxt_cEzL3_gPEQlGUInoIJgYQxxOEUFKumGdouvBsn-21iO5dspA-uUomSrTLuLtFVbZpG-kS2Ould53ujwjk4sbL2Zr6_Z-Dt8eF1-ZyuX55Wy_t1qgglIVUcG0UNxtRSjiTJSizjTCwvMg2hsYyXrGTRIMNyS3SRWy0VhZprTktbkhm4HvvGjz8H44NoKq9MXcvWdIMXmFLEKYUQ_U8R5jTuX7BIL_d0KBujRe-qRrqtOOQSARqBivt6Z6xQVZCh6trgZFULBMUufrGLX4zxx5qbHzWHtr_rq1F3Q_8n_AJ3y5PK
CitedBy_id crossref_primary_10_1002_prm2_12087
crossref_primary_10_1186_s12964_023_01341_8
crossref_primary_10_2174_1574892817666220524102403
crossref_primary_10_3389_fimmu_2022_928742
crossref_primary_10_1016_j_heliyon_2024_e29005
crossref_primary_10_1155_2022_6228982
crossref_primary_10_1093_gastro_goae083
crossref_primary_10_1155_2023_4674536
crossref_primary_10_1155_2022_2823042
crossref_primary_10_3389_fsurg_2022_897583
crossref_primary_10_3389_fgene_2022_938796
crossref_primary_10_3389_fonc_2024_1365550
crossref_primary_10_4251_wjgo_v16_i4_1268
crossref_primary_10_1080_15384101_2022_2075197
crossref_primary_10_3390_cancers16010196
crossref_primary_10_18632_aging_205158
crossref_primary_10_3389_fimmu_2023_1326031
crossref_primary_10_3389_fphar_2023_1216363
crossref_primary_10_1155_2022_5005498
crossref_primary_10_1186_s12876_023_03003_y
crossref_primary_10_1186_s43046_023_00192_1
crossref_primary_10_1155_2022_4105280
crossref_primary_10_3389_fgene_2021_796592
crossref_primary_10_2217_fmb_2023_0210
crossref_primary_10_1155_2022_7061263
crossref_primary_10_3389_fimmu_2023_1275461
crossref_primary_10_3389_fonc_2021_727306
crossref_primary_10_1111_jcmm_18174
crossref_primary_10_1097_MD_0000000000038979
crossref_primary_10_1155_2022_1964081
crossref_primary_10_1186_s12935_022_02493_2
crossref_primary_10_3389_fendo_2023_1224832
crossref_primary_10_3389_fimmu_2023_1297363
crossref_primary_10_3389_fimmu_2022_827506
crossref_primary_10_3389_fimmu_2022_977338
crossref_primary_10_1155_2021_9913952
crossref_primary_10_4251_wjgo_v16_i2_300
crossref_primary_10_3389_fonc_2023_1155418
crossref_primary_10_1016_j_clinsp_2022_100018
crossref_primary_10_5306_wjco_v14_i10_373
crossref_primary_10_1080_21655979_2022_2047398
crossref_primary_10_3389_fgene_2022_953997
crossref_primary_10_3390_pharmaceutics16121620
crossref_primary_10_1097_CM9_0000000000002185
crossref_primary_10_1016_j_tranon_2024_102181
crossref_primary_10_32604_or_2024_052207
crossref_primary_10_1007_s10528_024_10841_2
crossref_primary_10_1016_j_labinv_2025_104101
crossref_primary_10_1016_j_prp_2024_155156
crossref_primary_10_1002_tox_24338
crossref_primary_10_1155_2022_3035073
crossref_primary_10_1093_bfgp_elz003
crossref_primary_10_3389_fonc_2022_926404
crossref_primary_10_1002_cnr2_1959
crossref_primary_10_1016_j_heliyon_2024_e33674
crossref_primary_10_1007_s10495_023_01879_5
crossref_primary_10_1002_tox_24064
crossref_primary_10_2478_jtim_2023_0103
crossref_primary_10_3389_fgene_2022_843538
crossref_primary_10_12998_wjcc_v11_i4_738
crossref_primary_10_1038_s41598_023_33213_z
crossref_primary_10_1155_2022_3445230
crossref_primary_10_1016_j_gendis_2023_101164
crossref_primary_10_12677_acm_2024_1461853
crossref_primary_10_1016_j_cellsig_2023_111014
crossref_primary_10_3389_fimmu_2024_1375013
crossref_primary_10_1007_s12033_023_00896_8
crossref_primary_10_3390_biomedicines12030491
crossref_primary_10_3389_fgene_2022_765569
crossref_primary_10_12998_wjcc_v11_i20_4800
crossref_primary_10_1016_j_prp_2023_154962
crossref_primary_10_3389_fmolb_2022_889403
crossref_primary_10_2147_JIR_S422903
crossref_primary_10_1159_000531457
crossref_primary_10_1016_j_prp_2024_155252
crossref_primary_10_1093_carcin_bgae043
crossref_primary_10_3389_fgene_2021_798612
crossref_primary_10_3389_fgene_2022_935056
crossref_primary_10_1080_21655979_2021_1945522
crossref_primary_10_1089_cbr_2021_0357
crossref_primary_10_1007_s00432_022_04456_6
crossref_primary_10_1016_j_ecoenv_2024_116618
crossref_primary_10_1080_13102818_2020_1811767
crossref_primary_10_1016_j_trsl_2020_12_003
crossref_primary_10_1186_s12876_024_03430_5
crossref_primary_10_1186_s12885_024_12451_y
crossref_primary_10_3389_fimmu_2022_843077
crossref_primary_10_3748_wjg_v28_i37_5403
crossref_primary_10_1080_19932820_2023_2220153
crossref_primary_10_3748_wjg_v30_i24_3059
crossref_primary_10_3390_pharmaceutics14081576
crossref_primary_10_1155_2023_7123568
crossref_primary_10_31083_j_fbl2908279
crossref_primary_10_4103_ghep_ghep_24_24
crossref_primary_10_1007_s12033_023_00997_4
crossref_primary_10_1038_s41598_023_47631_6
crossref_primary_10_3390_cancers14030548
crossref_primary_10_3389_fcell_2021_797341
crossref_primary_10_1155_2022_2214686
crossref_primary_10_1371_journal_pone_0280989
Cites_doi 10.1172/JCI80011
10.1016/B978-0-12-407190-2.00007-1
10.1038/nrc3239
10.4251/wjgo.v7.i8.95
10.1016/S1470-2045(16)00175-3
10.1182/blood-2010-01-265975
10.1158/0008-5472.CAN-05-2213
10.1111/imr.12519
10.1056/NEJMoa1200694
10.3748/wjg.v21.i9.2777
10.1200/jco.2016.34.4_suppl.tps188
10.3892/ijo.2012.1573
10.1016/j.vaccine.2012.04.060
10.1158/1078-0432.CCR-09-2870
10.1002/(SICI)1097-0142(20000201)88:3<577::AID-CNCR13>3.0.CO;2-V
10.3748/wjg.v21.i37.10510
10.1200/JCO.2017.35.4_suppl.2
10.1056/NEJMoa1003466
10.1002/eji.200939274
10.1080/2162402X.2015.1100789
10.1038/nrc1782
10.1038/ncomms10501
10.1126/science.1235122
10.1002/cncr.21814
10.1158/1078-0432.CCR-06-1183
10.1016/j.humpath.2016.05.012
10.1200/JCO.2016.34.15_suppl.4011
10.4049/jimmunol.196.Supp.138.2
10.1158/0008-5472.CAN-11-0096
10.18632/oncotarget.14519
10.21037/jgo.2017.05.01
10.1080/17474086.2017.1313701
10.1200/JCO.2017.35.15_suppl.4012
10.1080/13543776.2016.1176150
10.1016/j.clinthera.2015.02.003
10.1007/s00439-016-1678-2
10.1038/nbt0816-796a
10.1182/blood-2010-04-281931
10.1200/JCO.2006.05.9964
10.1126/scitranslmed.3002842
10.1245/s10434-015-4931-3
10.1016/j.jcyt.2015.03.605
10.1007/s00262-012-1289-2
10.1182/blood-2014-12-615492
10.3322/caac.21262
ContentType Journal Article
Copyright The Author(s) 2018. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com 2018
The Author(s) 2018. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Copyright_xml – notice: The Author(s) 2018. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com 2018
– notice: The Author(s) 2018. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.
DBID AAYXX
CITATION
NPM
7X8
7S9
L.6
DOI 10.1093/bfgp/ely019
DatabaseName CrossRef
PubMed
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
DatabaseTitleList PubMed

MEDLINE - Academic
AGRICOLA
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2041-2657
EndPage 112
ExternalDocumentID 30388190
10_1093_bfgp_ely019
10.1093/bfgp/ely019
Genre Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: National Natural Science Foundation of China
  sequence: 0
  grantid: 81472714
  funderid: 10.13039/501100001809
GroupedDBID ---
.2P
.I3
0R~
4.4
48X
53G
5VS
6J9
70D
AAHBH
AAIMJ
AAJKP
AAJQQ
AAMDB
AAMVS
AAOGV
AAPQZ
AAPXW
AARHZ
AAUAY
AAUQX
AAVAP
AAVLN
ABDBF
ABEJV
ABEUO
ABIXL
ABJNI
ABMNT
ABNKS
ABPTD
ABQLI
ABQTQ
ABWST
ABXVV
ABZBJ
ACGFO
ACGFS
ACIWK
ACPRK
ACUFI
ADBBV
ADEYI
ADFTL
ADGKP
ADGZP
ADHKW
ADHZD
ADOCK
ADQBN
ADRIX
ADRTK
ADVEK
ADYVW
ADZTZ
ADZXQ
AEGPL
AEGXH
AEJOX
AEKSI
AELWJ
AEMDU
AENEX
AENZO
AEPUE
AETBJ
AEWNT
AFFZL
AFGWE
AFIYH
AFOFC
AFRAH
AFXEN
AGINJ
AGKEF
AGQXC
AGSYK
AHMBA
AHXPO
AIAGR
AIJHB
AJEEA
AKHUL
AKWXX
ALMA_UNASSIGNED_HOLDINGS
ALUQC
APIBT
APWMN
ARIXL
ATGXG
AXUDD
AYOIW
BAWUL
BAYMD
BCRHZ
BEYMZ
BHONS
BQDIO
BSWAC
C45
CDBKE
CZ4
DAKXR
DIK
DILTD
DU5
D~K
EAD
EAP
EAS
EBD
EBS
EE~
EJD
EMK
EMOBN
ESX
F5P
F9B
FHSFR
FLUFQ
FOEOM
FQBLK
GAUVT
GJXCC
GX1
H13
H5~
HAR
HW0
HZ~
IOX
J21
KBUDW
KOP
KSI
KSN
M-Z
M49
N9A
NGC
NLBLG
NOMLY
NU-
O0~
O9-
OAWHX
ODMLO
OJQWA
OJZSN
OK1
OVD
PAFKI
PEELM
PQQKQ
Q1.
Q5Y
RD5
ROX
RUSNO
RW1
RXO
SV3
TEORI
TLC
TR2
TUS
X7H
Y6R
YAYTL
YKOAZ
YXANX
~91
AAYXX
ABGNP
ABPQP
ABVGC
ABXZS
ACUHS
ADNBA
ADPDF
AHGBF
AJNCP
ALXQX
AMNDL
CITATION
JXSIZ
RPM
TOX
NPM
7X8
7S9
L.6
ID FETCH-LOGICAL-c353t-c92ec5e225f591a34b2a2658674d00ef89b8b82ec1e86f3d76fdac50d9d95bfb3
IEDL.DBID TOX
ISSN 2041-2657
IngestDate Fri Jul 11 09:37:20 EDT 2025
Fri Jul 11 02:44:54 EDT 2025
Wed Feb 19 02:36:04 EST 2025
Tue Jul 01 03:26:56 EDT 2025
Thu Apr 24 22:59:21 EDT 2025
Fri Dec 06 10:16:17 EST 2024
IsPeerReviewed false
IsScholarly true
Issue 2
Keywords immunogenomics
immune checkpoint inhibitor
gastric cancer
biomarkers
Language English
License This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)
https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model
The Author(s) 2018. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c353t-c92ec5e225f591a34b2a2658674d00ef89b8b82ec1e86f3d76fdac50d9d95bfb3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
PMID 30388190
PQID 2129541078
PQPubID 23479
PageCount 6
ParticipantIDs proquest_miscellaneous_2551955001
proquest_miscellaneous_2129541078
pubmed_primary_30388190
crossref_citationtrail_10_1093_bfgp_ely019
crossref_primary_10_1093_bfgp_ely019
oup_primary_10_1093_bfgp_ely019
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2019-03-22
PublicationDateYYYYMMDD 2019-03-22
PublicationDate_xml – month: 03
  year: 2019
  text: 2019-03-22
  day: 22
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Briefings in functional genomics
PublicationTitleAlternate Brief Funct Genomics
PublicationYear 2019
Publisher Oxford University Press
Publisher_xml – sequence: 0
  name: Oxford University Press
References Zhang ( key 2019032209391961900_ely019-B45) 2015; 21
Charles ( key 2019032209391961900_ely019-B16) 2018; 4
Chen ( key 2019032209391961900_ely019-B8) 2015; 125
key 2019032209391961900_ely019-B19
key 2019032209391961900_ely019-B18
Ralph ( key 2019032209391961900_ely019-B12) 2010; 16
Cho ( key 2019032209391961900_ely019-B52) 2017; 8
Ishigami ( key 2019032209391961900_ely019-B39) 2000; 88
Ajani ( key 2019032209391961900_ely019-B40) 2006; 106
Andrews ( key 2019032209391961900_ely019-B33) 2017; 276
Hodi ( key 2019032209391961900_ely019-B4) 2010; 363
Brahmer ( key 2019032209391961900_ely019-B3) 2012; 366
( key 2019032209391961900_ely019-B49) 2014; 513
Masuzawa ( key 2019032209391961900_ely019-B41) 2012; 41
Ulmer ( key 2019032209391961900_ely019-B43) 2012; 30
Marrelli ( key 2019032209391961900_ely019-B6) 2016; 23
key 2019032209391961900_ely019-B22
key 2019032209391961900_ely019-B21
Le ( key 2019032209391961900_ely019-B23) 2016; 34(4_suppl)
Lamers ( key 2019032209391961900_ely019-B56) 2006; 24
Schlößer ( key 2019032209391961900_ely019-B53) 2016; 5
Eisenächer ( key 2019032209391961900_ely019-B44) 2007; 212
Collin ( key 2019032209391961900_ely019-B10) 2016; 26
Ngiow ( key 2019032209391961900_ely019-B31) 2011; 71
Muro ( key 2019032209391961900_ely019-B15) 2016; 17
Donato ( key 2019032209391961900_ely019-B2) 2017; 10
Oh ( key 2019032209391961900_ely019-B20) 2016; 34(4_suppl)
Kochenderfer ( key 2019032209391961900_ely019-B57) 2010; 116
Cui ( key 2019032209391961900_ely019-B34) 2014; 17
Guo ( key 2019032209391961900_ely019-B42) 2013; 119
Brown ( key 2019032209391961900_ely019-B59) 2016; 196(1 Suppl)
Yung ( key 2019032209391961900_ely019-B17) 2017; 35
Shi ( key 2019032209391961900_ely019-B37) 2012; 61
Muller ( key 2019032209391961900_ely019-B28) 2005; 65
Koyama ( key 2019032209391961900_ely019-B30) 2016; 7
Hastings ( key 2019032209391961900_ely019-B29) 2009; 39
Torre ( key 2019032209391961900_ely019-B1) 2015; 65
Janjigian ( key 2019032209391961900_ely019-B26) 2016; 34(4_suppl)
Kang ( key 2019032209391961900_ely019-B24) 2017; 35(4_suppl)
Cui ( key 2019032209391961900_ely019-B36) 2015; 17
Chen ( key 2019032209391961900_ely019-B38) 2015; 8
Vogelstein ( key 2019032209391961900_ely019-B48) 2013; 339
Kim ( key 2019032209391961900_ely019-B51) 2015; 148
Moehler ( key 2019032209391961900_ely019-B14) 2016; 34
Kershaw ( key 2019032209391961900_ely019-B55) 2006; 12
de Visser ( key 2019032209391961900_ely019-B7) 2006; 6
Song ( key 2019032209391961900_ely019-B47) 2017
Li ( key 2019032209391961900_ely019-B54) 2016; 55
Park ( key 2019032209391961900_ely019-B9) 2010; 116
Raufi ( key 2019032209391961900_ely019-B27) 2015; 6
Buchbinder ( key 2019032209391961900_ely019-B13) 2015; 37
( key 2019032209391961900_ely019-B62) 2016; 34
University SMM ( key 2019032209391961900_ely019-B46) 2000
Grierson ( key 2019032209391961900_ely019-B11) 2017; 8
Benjamin ( key 2019032209391961900_ely019-B61) 2016; 135
Zhang ( key 2019032209391961900_ely019-B50) 2014; 33
Pardoll ( key 2019032209391961900_ely019-B32) 2012; 12
Kalos ( key 2019032209391961900_ely019-B58) 2011; 3
de Guillebon ( key 2019032209391961900_ely019-B25) 2015; 7
Sharma ( key 2019032209391961900_ely019-B60) 2015; 126
Jiang ( key 2019032209391961900_ely019-B35) 2006; 26
Hudler ( key 2019032209391961900_ely019-B5) 2015; 21
References_xml – volume: 125
  start-page: 3384
  issue: 9
  year: 2015
  ident: key 2019032209391961900_ely019-B8
  article-title: Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future
  publication-title: J Clin Invest
  doi: 10.1172/JCI80011
– volume: 119
  start-page: 421
  year: 2013
  ident: key 2019032209391961900_ely019-B42
  article-title: Therapeutic cancer vaccines: past, present, and future
  publication-title: Adv Cancer Res
  doi: 10.1016/B978-0-12-407190-2.00007-1
– volume: 12
  start-page: 252
  issue: 4
  year: 2012
  ident: key 2019032209391961900_ely019-B32
  article-title: The blockade of immune checkpoints in cancer immunotherapy
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc3239
– volume: 7
  start-page: 95
  issue: 8
  year: 2015
  ident: key 2019032209391961900_ely019-B25
  article-title: Anti program death-1/anti program death-ligand 1 in digestive cancers
  publication-title: World J Gastrointest Oncol
  doi: 10.4251/wjgo.v7.i8.95
– volume: 17
  start-page: 717
  issue: 6
  year: 2016
  ident: key 2019032209391961900_ely019-B15
  article-title: Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(16)00175-3
– volume: 116
  start-page: 1291
  issue: 8
  year: 2010
  ident: key 2019032209391961900_ely019-B9
  article-title: B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance
  publication-title: Blood
  doi: 10.1182/blood-2010-01-265975
– volume: 4
  start-page: e180013
  issue: 5
  year: 2018
  ident: key 2019032209391961900_ely019-B16
  article-title: KEYNOTE-059 cohort 1: efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer
  publication-title: J Clin Oncol
– volume: 65
  start-page: 8065
  issue: 18
  year: 2005
  ident: key 2019032209391961900_ely019-B28
  article-title: Marrying immunotherapy with chemotherapy: why say IDO
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-05-2213
– ident: key 2019032209391961900_ely019-B19
– volume: 276
  start-page: 80.
  issue: 1
  year: 2017
  ident: key 2019032209391961900_ely019-B33
  article-title: LAG3 (CD223) as a cancer immunotherapy target
  publication-title: Immunol Rev
  doi: 10.1111/imr.12519
– volume: 366
  start-page: 2455
  issue: 26
  year: 2012
  ident: key 2019032209391961900_ely019-B3
  article-title: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1200694
– volume: 21
  start-page: 2777.
  issue: 9
  year: 2015
  ident: key 2019032209391961900_ely019-B45
  article-title: Prolonged overall survival in gastric cancer patients after adoptive immunotherapy
  publication-title: World J Gastroenterol
  doi: 10.3748/wjg.v21.i9.2777
– ident: key 2019032209391961900_ely019-B21
– volume: 33
  start-page: 469
  issue: 10
  year: 2014
  ident: key 2019032209391961900_ely019-B50
  article-title: TCGA divides gastric cancer into four molecular subtypes: implications for individualized therapeutics
  publication-title: Chin J Cancer
– volume: 34(4_suppl)
  start-page: TPS188
  year: 2016
  ident: key 2019032209391961900_ely019-B20
  article-title: Avelumab (MSB0010718C), an anti-PD-L1 antibody, as a third-line treatment in patients with advanced gastric or gastroesophageal junction cancer: a phase Ib JAVELIN solid tumor trial
  publication-title: J Clin Oncol
  doi: 10.1200/jco.2016.34.4_suppl.tps188
– volume: 41
  start-page: 1297
  issue: 4
  year: 2012
  ident: key 2019032209391961900_ely019-B41
  article-title: Phase I/II study of S-l plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer
  publication-title: Int J Oncol
  doi: 10.3892/ijo.2012.1573
– volume: 34(4_suppl)
  year: 2016
  ident: key 2019032209391961900_ely019-B23
  article-title: Safety and activity of nivolumab monotherapy in advanced and metastatic (A/M) gastric or gastroesophageal junction cancer (GC/GEC): results from the CheckMate-032 study
  publication-title: J Clin Oncol
– volume: 30
  start-page: 4414
  issue: 30
  year: 2012
  ident: key 2019032209391961900_ely019-B43
  article-title: RNA-based vaccines
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2012.04.060
– volume: 16
  start-page: 1662
  issue: 5
  year: 2010
  ident: key 2019032209391961900_ely019-B12
  article-title: Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-09-2870
– volume: 34(4_suppl)
  start-page: 6
  year: 2016
  ident: key 2019032209391961900_ely019-B26
  article-title: CheckMate-032: phase I/II, open-label study of safety and activity of nivolumab(nivo) alone or with ipilimumab (ipi) in advanced and metastatic (A/M) gastric cancer (GC)
  publication-title: J Clin Oncol
– volume: 88
  start-page: 577
  issue: 3
  year: 2000
  ident: key 2019032209391961900_ely019-B39
  article-title: Prognostic value of intratumoral natural killer cells in gastric carcinoma
  publication-title: Cancer
  doi: 10.1002/(SICI)1097-0142(20000201)88:3<577::AID-CNCR13>3.0.CO;2-V
– volume: 513
  start-page: 143
  issue: 7517
  year: 2014
  ident: key 2019032209391961900_ely019-B49
  article-title: Comprehensive molecular characterization of gastric adenocarcinoma
  publication-title: Nature
– volume: 21
  start-page: 10510
  issue: 37
  year: 2015
  ident: key 2019032209391961900_ely019-B5
  article-title: Challenges of deciphering gastric cancer heterogeneity
  publication-title: World J Gastroenterol
  doi: 10.3748/wjg.v21.i37.10510
– volume: 35(4_suppl)
  start-page: 2
  year: 2017
  ident: key 2019032209391961900_ely019-B24
  article-title: Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastroesophageal junction cancer (AGC): a double-blinded, randomized, phase III trial
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2017.35.4_suppl.2
– volume: 363
  start-page: 711
  issue: 8
  year: 2010
  ident: key 2019032209391961900_ely019-B4
  article-title: Improved survival with ipilimumab in patients with metastatic melanoma
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1003466
– volume: 39
  start-page: 2492
  issue: 9
  year: 2009
  ident: key 2019032209391961900_ely019-B29
  article-title: TIM-3 is expressed on activated human CD4+ T cells and regulates Th1 and Th17 cytokines
  publication-title: Eur J Immunol
  doi: 10.1002/eji.200939274
– volume: 5
  start-page: e1100789.
  issue: 5
  year: 2016
  ident: key 2019032209391961900_ely019-B53
  article-title: Immune checkpoints programmed death 1 ligand 1 and cytotoxic T lymphocyte associated molecule 4 in gastric adenocarcinoma
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2015.1100789
– volume: 6
  start-page: 24
  issue: 1
  year: 2006
  ident: key 2019032209391961900_ely019-B7
  article-title: Paradoxical roles of the immune system during cancer development
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc1782
– ident: key 2019032209391961900_ely019-B18
– volume: 7
  start-page: 10501.
  year: 2016
  ident: key 2019032209391961900_ely019-B30
  article-title: Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
  publication-title: Nat Commun
  doi: 10.1038/ncomms10501
– volume: 8
  start-page: 7728
  issue: 5
  year: 2015
  ident: key 2019032209391961900_ely019-B38
  article-title: Efficacy of adjuvant chemotherapy combined with immunotherapy with cytokine-induced killer cells for gastric cancer after d2 gastrectomy
  publication-title: Int J Clin Exp Med
– volume: 339
  start-page: 1546
  issue: 6127
  year: 2013
  ident: key 2019032209391961900_ely019-B48
  article-title: Cancer genome landscapes
  publication-title: Science
  doi: 10.1126/science.1235122
– volume: 106
  start-page: 1908
  issue: 9
  year: 2006
  ident: key 2019032209391961900_ely019-B40
  article-title: An open-label, multinational, multicenter study of G17DT Vaccination combined with cisplatin and 5-nuorouracil in patients with untreated, advanced gastric or gastroesophageal cancer: the GC4 study
  publication-title: Cancer
  doi: 10.1002/cncr.21814
– volume: 12
  start-page: 6106
  issue: 20 Pt 1
  year: 2006
  ident: key 2019032209391961900_ely019-B55
  article-title: A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-06-1183
– volume: 55
  start-page: 182
  year: 2016
  ident: key 2019032209391961900_ely019-B54
  article-title: PD-L1 expression is associated with massive lymphocyte infiltration and histology in gastric cancer
  publication-title: Hum Pathol
  doi: 10.1016/j.humpath.2016.05.012
– volume: 34
  start-page: 4011
  year: 2016
  ident: key 2019032209391961900_ely019-B14
  article-title: A randomized, openlabel, two-arm phase II trial comparing the efficacy of sequential ipilimumab (ipi) versus best supportive care (BSC) following first-line (1L) chemotherapy in patients with unresectable, locally advanced/metastatic (A/M) gastric or gastro-esophageal junction (G/GEJ) cancer
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2016.34.15_suppl.4011
– volume: 196(1 Suppl)
  start-page: 138.2
  year: 2016
  ident: key 2019032209391961900_ely019-B59
  article-title: T cell receptor knockout efficiency utilizing an engineered meganuclease is influenced by stimulation conditions
  publication-title: J Immunol
  doi: 10.4049/jimmunol.196.Supp.138.2
– volume: 71
  start-page: 3540
  issue: 10
  year: 2011
  ident: key 2019032209391961900_ely019-B31
  article-title: Anti-TIM3 antibody promotes T cell IFN-gamma-mediated antitumor immunity and suppresses established tumors
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-11-0096
– volume: 26
  start-page: 2237
  issue: 3B
  year: 2006
  ident: key 2019032209391961900_ely019-B35
  article-title: Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells
  publication-title: Anticancer Res
– volume: 8
  start-page: 13320
  issue: 8
  year: 2017
  ident: key 2019032209391961900_ely019-B52
  article-title: Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.14519
– volume: 8
  start-page: 474
  issue: 3
  year: 2017
  ident: key 2019032209391961900_ely019-B11
  article-title: Immunotherapy in gastrointestinal cancers
  publication-title: J Gastrointest Oncol
  doi: 10.21037/jgo.2017.05.01
– volume: 10
  start-page: 417
  issue: 5
  year: 2017
  ident: key 2019032209391961900_ely019-B2
  article-title: Immunotherapy for the treatment of Hodgkin lymphoma
  publication-title: Expert Rev Hematol
  doi: 10.1080/17474086.2017.1313701
– volume: 35
  start-page: 4012
  year: 2017
  ident: key 2019032209391961900_ely019-B17
  article-title: KEYNOTE-059 cohort 2: safety and efficacy of pembrolizumab (pembro) plus 5-fluorouracil (5-FU) and cisplatin for first-line (1L) treatment of advanced gastric cancer
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2017.35.15_suppl.4012
– volume: 26
  start-page: 555
  issue: 5
  year: 2016
  ident: key 2019032209391961900_ely019-B10
  article-title: Immune checkpoint inhibitors: a patent review (2010-2015)
  publication-title: Expert Opin Ther Pat
  doi: 10.1080/13543776.2016.1176150
– volume: 37
  start-page: 755
  issue: 4
  year: 2015
  ident: key 2019032209391961900_ely019-B13
  article-title: Cytotoxic T-lymphocyte antigen-4 blockade in melanoma
  publication-title: Clin Ther
  doi: 10.1016/j.clinthera.2015.02.003
– volume: 212
  start-page: 701
  issue: 9–10
  year: 2007
  ident: key 2019032209391961900_ely019-B44
  article-title: The role of viral nucleic acid recognition in dendritic cells for innate and adaptive antiviral immunity
  publication-title: Immunobiology
– volume: 135
  start-page: 1059
  issue: 9
  year: 2016
  ident: key 2019032209391961900_ely019-B61
  article-title: TALEN gene editing takes aim on HIV
  publication-title: Hum Genet
  doi: 10.1007/s00439-016-1678-2
– volume: 148
  start-page: 137
  issue: 1
  year: 2015
  ident: key 2019032209391961900_ely019-B51
  article-title: Deregulation of immune response genes in patients with Epstein-Barr virLls-associated gastric cancer and outcomes
  publication-title: Gastmentemlogy
– year: 2000
  ident: key 2019032209391961900_ely019-B46
– volume: 34
  start-page: 796.
  issue: 8
  year: 2016
  ident: key 2019032209391961900_ely019-B62
  article-title: First-in-human CRISPR trial
  publication-title: Nat Biotech
  doi: 10.1038/nbt0816-796a
– volume: 17
  start-page: 698
  issue: 7
  year: 2014
  ident: key 2019032209391961900_ely019-B34
  article-title: Clinical study of autologous cytokine-induced killer cells combined with XELOX regimen in the treatment of senile advanced gastric cancer [in Chinese]
  publication-title: Zhonghua Wei Chang Wai Ke Za Zhi
– volume: 116
  start-page: 4099
  issue: 20
  year: 2010
  ident: key 2019032209391961900_ely019-B57
  article-title: Eradication of B-lineage cells and regression of lymphomaina patient treated with autologous T cells genetically engineered to recognize CD19
  publication-title: Blood
  doi: 10.1182/blood-2010-04-281931
– start-page: 1
  issue: 241–252
  year: 2017
  ident: key 2019032209391961900_ely019-B47
  article-title: Effective and persistent antitumor activity of HER2-directed CAR-T cells against gastric cancer cells in vitro and xenotransplanted tumors in vivo
  publication-title: Protein Cell
– volume: 24
  start-page: e20
  issue: 13
  year: 2006
  ident: key 2019032209391961900_ely019-B56
  article-title: Treatmentof metastatic renal cell carcinomawith autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2006.05.9964
– volume: 3
  start-page: 95ra73.
  issue: 95
  year: 2011
  ident: key 2019032209391961900_ely019-B58
  article-title: T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia
  publication-title: Sci Transl Med
  doi: 10.1126/scitranslmed.3002842
– volume: 23
  start-page: 943
  issue: 3
  year: 2016
  ident: key 2019032209391961900_ely019-B6
  article-title: Strong prognostic value of microsatellite instability in intestinal type non-cardia gastric cancer
  publication-title: Ann Surg Oncol
  doi: 10.1245/s10434-015-4931-3
– volume: 17
  start-page: 979
  issue: 7
  year: 2015
  ident: key 2019032209391961900_ely019-B36
  article-title: Combined cellular immunotherapy and chemotherapy improves clinical outcome in patients with gastric carcinoma
  publication-title: Cytotherapy
  doi: 10.1016/j.jcyt.2015.03.605
– volume: 61
  start-page: 2251
  issue: 12
  year: 2012
  ident: key 2019032209391961900_ely019-B37
  article-title: Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer
  publication-title: Cancer Immunol Immunother
  doi: 10.1007/s00262-012-1289-2
– volume: 6
  start-page: 561
  issue: 5
  year: 2015
  ident: key 2019032209391961900_ely019-B27
  article-title: Immunotherapy for advanced gastric and esophageal cancer: preclinical rationale and ongoing clinical investigations
  publication-title: J Gastrointest Oncol
– ident: key 2019032209391961900_ely019-B22
– volume: 126
  start-page: 1777
  issue: 15
  year: 2015
  ident: key 2019032209391961900_ely019-B60
  article-title: In vivo genome editing of the albumin locus as a platform for protein replacement therapy
  publication-title: Blood
  doi: 10.1182/blood-2014-12-615492
– volume: 65
  start-page: 87
  issue: 2
  year: 2015
  ident: key 2019032209391961900_ely019-B1
  article-title: Global cancer statistics, 2012
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21262
SSID ssj0000314410
Score 2.5245657
SecondaryResourceType review_article
Snippet Abstract Gastric cancer remains the second most common cause of cancer-related death worldwide. Because of the poor prognosis of late-stage gastric cancer...
Gastric cancer remains the second most common cause of cancer-related death worldwide. Because of the poor prognosis of late-stage gastric cancer patients, it...
SourceID proquest
pubmed
crossref
oup
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 107
SubjectTerms biomarkers
breast neoplasms
death
genome
genomics
immune system
immunotherapy
lung neoplasms
prognosis
stomach neoplasms
survival rate
Title Immunotherapy for gastric cancer: dilemmas and prospect
URI https://www.ncbi.nlm.nih.gov/pubmed/30388190
https://www.proquest.com/docview/2129541078
https://www.proquest.com/docview/2551955001
Volume 18
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1LSwMxEA5SELyIb-ujRuhJWJpuNpvEm4ilCuqlhd6WPHtpt6WPQ_-9k91toVrq_QsJMwnzJZP5BqEmlUwR32aRNXESJToxkRCGwi2FSm9oTGzRi-DzK-32k48BG1QfZOc7UviStrQfTltutCKFuieE3yCR3_sebJ5SggJ70iZV9d2vIVvxZquG7Q-VLEJK5wQdV1wQv5TOO0UHLj9Dh2V3yNU54u-hdqOqkFphYJd4qEKbDYNN8NXsGVs40-OxmmOVWwzzFXWTF6jfeeu9dqOqz0FkKKOLyMjYGebgZHkm24omOlYxMIOUJ5YQ54XUQgvAtJ1IPbU89VYZRqy0kmmv6SWq5ZPcXSPsLPGKcaUtN3D14dorESS8HLfWCEXr6GltjcxUIuChF8UoK5PRNAumy0rT1VFzA56W2he7YQ9g1v2Ix7XJM9i9ISWhcjdZzjMInJKB77jYg2FBAYdBPK2jq9Jfm8loELMBTnPz7xpu0RFwHRm-j8XxHaotZkt3D3xioRvFE0-j2FM_T-zLuA
linkProvider Oxford University Press
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Immunotherapy+for+gastric+cancer%3A+dilemmas+and+prospect&rft.jtitle=Briefings+in+functional+genomics&rft.au=Zhao%2C+Qingfang&rft.au=Cao%2C+Liang&rft.au=Guan%2C+Lulu&rft.au=Bie%2C+Liangyu&rft.date=2019-03-22&rft.pub=Oxford+University+Press&rft.eissn=2041-2657&rft.volume=18&rft.issue=2&rft.spage=107&rft.epage=112&rft_id=info:doi/10.1093%2Fbfgp%2Fely019&rft.externalDocID=10.1093%2Fbfgp%2Fely019
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2041-2657&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2041-2657&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2041-2657&client=summon